Human Genome Sciences (HGSI) and GlaxoSmithKline PLC (GSK) announced Monday morning that BENLYSTA met the primary endpoint in the second of two Phase 3 trials in seropositive patients with systemic lupus erythematosus.
Human Genome Sciences gapped open sharply higher Monday and is now up 7.01 at $25.70 on above average volume. The stock has broken out of a 2-month range and is now trading at a new high for the year.
For comments and feedback: editorial@rttnews.com